[1]
|
Suerbaum, S. and Michetti, P. (2002) Helicobacter pylori Infection. The New England Journal of Medicine, 347, 1175-1186. https://doi.org/10.1056/NEJMra020542
|
[2]
|
Malfertheiner, P., Megraud, F., O’Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D.Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K. and El-Omar, E.M. (2017) European Helicobacter and Microbiota Study Group and Consensus panel.Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report. Gut, 66, 6-30. https://doi.org/10.1136/gutjnl-2016-312288
|
[3]
|
Fallone, C.A., Chiba, N., van Zanten, S.V., Fischbach, L., Gisbert, J.P., Hunt, R.H., Jones, N.L., Render, C., Leontiadis, G.I., Moayyedi, P. and Marshall, J.K. (2016) The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 151, 51-69. https://doi.org/10.1053/j.gastro.2016.04.006
|
[4]
|
World Health Organization (2014) H. pylori Eradication as a Strategy for Preventing Gastric Cancer.
http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/Helicobacter_pylori_Eradication.pdf
|
[5]
|
Kusano, C., Gotoda, T., Ishikawa, H. and Moriyama, M. (2017) The Administrative Project of Helicobacter pylori Infection Screening among Junior High School Students in an Area of Japan with a High Incidence of Gastric Cancer. Gastric Cancer, 20, 16-19.
|
[6]
|
Wang, B., Lv, Z.F., Wang, Y.H., Wang, H., Liu, X.Q., Xie, Y. and Zhou, X.J. (2014) Standard Triple Therapy for Helicobacter pylori Infection in China: A Meta-Analysis. World Journal of Gastroenterology, 20, 14973-14985.
https://doi.org/10.3748/wjg.v20.i40.14973
|
[7]
|
Graham, D.Y. and Fischbach, L. (2010) Helicobacter pylori Treatment in the Era of Increasing Antibiotic Resistance. Gut, 59, 1143-1153.
https://doi.org/10.1136/gut.2009.192757
|
[8]
|
Zhang, M. (2015) High Antibiotic Resistance Rate: A Difficult Issue for Helicobacter pylori Eradication Treatment. World Journal of Gastroenterology, 21, 13432-13437. https://doi.org/10.3748/wjg.v21.i48.13432
|
[9]
|
Jung, S.M., Cheung, D.Y., Kim, J.I., Kim, I. and Seong, H. (2016) Comparing the Efficacy of Concomitant Therapy with Sequential Therapy as the First-Line Therapy of Helicobacter pylori Eradication. Gastroenterology Research and Practice, 2016, Article ID: 1293649. https://doi.org/10.1155/2016/1293649
|
[10]
|
Tepes, B., Vujasinovic, M., Seruga, M., Stefanovic, M., Forte, A. and Jeverica, S. (2016) Randomized Clinical Trial Comparing 10-Day Sequential, 7-Day Concomitant and 7-Day Standard Triple Therapies for Helicobacter pylori Eradication. European Journal of Gastroenterology & Hepatology, 28, 676-683.
https://doi.org/10.1097/MEG.0000000000000590
|
[11]
|
Hori, Y., Imanishi, A., Matsukawa, J., Tsukimi, Y., Nishida, H., Arikawa, Y., Hirase, K., Kajino, M. and Inatomi, N. (2010) 1-[5-(2-Fluorophenyl)-1-(pyridine 3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases. Journal of Pharmacology and Experimental Therapeutics, 335, 231-238. https://doi.org/10.1124/jpet.110.170274
|
[12]
|
Sakurai, Y., Nishimura, A., Kennedy, G., Hibberd, M., Jenkins, R., Okamoto, H., Yoneyama, T., Jenkins, H., Ashida, K., Irie, S. and Täubel, J. (2015) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/Non-Japanese Subjects. Clinical and Translational Gastroenterology, 6, e94. https://doi.org/10.1038/ctg.2015.18
|
[13]
|
Murakami, K., Sakurai, Y., Shiino, M., Funao, N., Nishimura, A. and Asaka, M. (2016) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study. Gut, 65, 1439-1446.
https://doi.org/10.1136/gutjnl-2015-311304
|
[14]
|
Suzuki, S., Gotoda, T., Kusano, C., Iwatsuka, K. and Moriyama, M. (2016) The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared with a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. The American Journal of Gastroenterology, 111, 949-956.
https://doi.org/10.1038/ajg.2016.182
|
[15]
|
Matsumoto, H., Shiotani, A., Katsumata, R., Fujita, M., Nakato, R., Murao, T., Ishii, M., Kamada, T., Haruma, K. and Graham, D.Y. (2016) Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Digestive Diseases and Sciences, 61, 3215-3220.
https://doi.org/10.1007/s10620-016-4305-0
|
[16]
|
Yamada, S., Kawakami, T., Nakatsugawa, Y., Suzuki, T., Fujii, H., Tomatsuri, N., Nakamura, H., Sato, H., Okuyama, Y., Kimura, H. and Yoshida, N. (2016) Usefulness of Vonoprazan, a Potassium Ion-Competitive Acid Blocker, for Primary Eradication of Helicobacter pylori. World Journal of Gastrointestinal Pharmacology and Therapeutics, 7, 550-555. https://doi.org/10.4292/wjgpt.v7.i4.550
|
[17]
|
Noda, H., Noguchi, S., Yoshimine, T., Goji, S., Adachi, K., Tamura, Y., Izawa, S., Ebi, M., Yamamoto, S., Ogasawara, N., Funaki, Y., Sasaki, M. and Kasugai, K. (2016) A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-Containing 7-Day Triple Therapy against Helicobacter pylori. Journal of Gastrointestinal and Liver Diseases, 25, 283-288.
|
[18]
|
Kajihara, Y., Shimoyama, T. and Mizuki, I. (2017) Analysis of the Cost-Effectiveness of Using Vonoprazan-Amoxicillin-Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication. Scandinavian Journal of Gastroenterology, 52, 238-241. https://doi.org/10.1080/00365521.2016.1250157
|
[19]
|
Shinozaki, S., Nomoto, H., Kondo, Y., Sakamoto, H., Hayashi, Y., Yamamoto, H., Lefor, A.K. and Osawa, H. (2016) Comparison of Vonoprazan and Proton Pump Inhibitors for Eradication of Helicobacter pylori. The Kaohsiung Journal of Medical Sciences, 32, 255-260.
|
[20]
|
Shichijo, S., Hirata, Y., Niikura, R., Hayakawa, Y., Yamada, A., Mochizuki, S., Matsuo, K., Isomura, Y., Seto, M., Suzuki, N., Suzuki, H., Yamamoto, S., Sugimoto, T., Omae, T., Okamoto, M., Watabe, H., Togo, G., Takano, N., Fukui, K., Ito, Y. and Koike, K. (2016) Vonoprazan versus Conventional Proton Pump Inhibitor-Based Triple Therapy as First-Line Treatment against Helicobacter pylori: A Multicenter Retrospective Study in Clinical Practice. Journal of Digestive Diseases, 17, 670-675.
https://doi.org/10.1111/1751-2980.12398
|
[21]
|
Sakurai, K., Suda, H., Ido, Y., Takeichi, T., Okuda, A., Hasuda, K. and Hattori, M. (2017) Comparative Study: Vonoprazan and Proton Pump Inhibitors in Helicobacter pylori Eradication Therapy. World Journal of Gastroenterology, 23, 668-675.
https://doi.org/10.3748/wjg.v23.i4.668
|
[22]
|
Tsujimae, M., Yamashita, H., Hashimura, H., Kano, C., Shimoyama, K., Kanamori, A., Matsumoto, K., Koizumi, A., Momose, K., Eguchi, T., Fukuchi, T., Fujita, M. and Okada, A. (2016) A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. Digestion, 94, 240-246. https://doi.org/10.1159/000454762
|
[23]
|
Nishizawa, T., Suzuki, H., Fujimoto, A., Kinoshita, H., Yoshida, S., Isomura, Y., Toyoshima, A., Kanai, T., Yahagi, N. and Toyoshima, O. (2017) Effects of Patient Age and Choice of Antisecretory Agent on Success of Eradication Therapy for Helicobacter pylori Infection. Journal of Clinical Biochemistry and Nutrition, 60, 208-210. https://doi.org/10.3164/jcbn.16-86
|
[24]
|
Tanabe, H., Ando, K., Sato, K., Ito, T., Goto, M., Sato, T., Fujinaga, A., Kawamoto, T., Utsumi, T., Yanagawa, N., Ichiishi, E., Otake, T., Kohgo, Y., Nomura, Y., Ueno, N., Sugano, H., Kashima, S., Moriichi, K., Fujiya, M. and Okumura, T. (2017) Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. Digestive Diseases and Sciences.
https://doi.org/10.1007/s10620-017-4664-1
|
[25]
|
Jung, Y.S., Kim, E.H. and Park, C.H. (2017) Systematic Review with Meta-Analysis: The Efficacy of Vonoprazan-Based Triple Therapy on Helicobacter pylori Eradication. Alimentary Pharmacology & Therapeutics, 46, 106-114.
https://doi.org/10.1111/apt.14130
|
[26]
|
Maruyama, M., Tanaka, N., Kubota, D., Miyajima, M., Kimura, T., Tokutake, K., Imai, R., Fujisawa, T., Mori, H., Matsuda, Y., Wada, S., Horiuchi, A. and Kiyosawa, K. (2017) Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial. Canadian Journal of Gastroenterology and Hepatology.
https://doi.org/10.1155/2017/4385161
|
[27]
|
Sue, S., Kuwashima, H., Iwata, Y., Oka, H., Arima, I., Fukuchi, T., Sanga, K., Inokuchi, Y., Ishii, Y., Kanno, M., Terada, M., Amano, H., Naito, M., Iwase, S., Okazaki, H., Komatsu, K., Kokawa, A., Kawana, I., Morimoto, M., Saito, T., Kunishi, Y., Ikeda, A., Takahashi, D., Miwa, H., Sasaki, T., Tamura, T., Kondo, M., Shibata, W. and Maeda, S. (2017) The Superiority of Vonoprazan-Based First-Line Triple Therapy with Clarithromycin: A Prospective Multi-Center Cohort Study on Helicobacter pylori Eradication., 56, 1277-1285.
https://doi.org/10.2169/internalmedicine.56.7833
|
[28]
|
Aoyama, N., Shigeta, S. and Yokozaki, H. (2017) Comparison of H. pylori Antibody between E-Plate (ELISA) and Latex Agglutination Method (LATEX) among Strictly Diagnosed H. pylori Infection Status. Japanese Journal of Helicobacter Research, 18, 4-11.
|
[29]
|
Kimura, K. and Takemoto, T. (1969) An Endoscopic Recognition of the Atrophic Border and Its Significance in Chronic Gastritis. Endoscopy, 1, 87-97.
https://doi.org/10.1055/s-0028-1098086
|
[30]
|
Lindenauer, P.K., Pekow, P., Wang, K., Mamidi, D.K., Gutierrez, B. and Benjamin, E.M. (2005) Perioperative Beta-Blocker Therapy and Mortality after Major Noncardiac Surgery. The New England Journal of Medicine, 353, 349-361.
https://doi.org/10.1056/NEJMoa041895
|
[31]
|
Lee, J.Y., Kim, N., Kim, M.S., Choi, Y.J., Lee, J.W., Yoon, H., Shin, C.M., Park, Y.S., Lee, D.H. and Jung, H.C. (2014) Factors Affecting First-Line Triple Therapy of Helicobacter pylori Including CYP2C19 Genotype and Antibiotic Resistance. Digestive Diseases and Sciences, 59, 1235-1243. https://doi.org/10.1007/s10620-014-3093-7
|
[32]
|
Jenkins, H., Sakurai, Y., Nishimura, A., Okamoto, H., Hibberd, M., Jenkins, R., Yoneyama, T., Ashida, K., Ogama, Y. and Warrington, S. (2015) Randomised Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Doses of TAK-438 (Vonoprazan), a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects. Alimentary Pharmacology & Therapeutics, 41, 636-648.
https://doi.org/10.1111/apt.13121
|
[33]
|
Adachi, K., Katsube, T., Kawamura, A., Takashima, T., Yuki, M., Amano, K., Ishihara, S., Fukuda, R., Watanabe, M. and Kinoshita, Y. (2000) CYP2C19 Genotype Status and Intragastric pH during Dosing with Lansoprazole or Rabeprazole. Alimentary Pharmacology & Therapeutics, 14, 1259-1266.
https://doi.org/10.1046/j.1365-2036.2000.00840.x
|
[34]
|
Labenz, J. (2001) Current Role of Acid Suppressants in Helicobacter pylori Eradication Therapy. Best Practice & Research: Clinical Gastroenterology, 15, 413-431.
https://doi.org/10.1053/bega.2001.0188
|
[35]
|
Sugimoto, M., Furuta, T., Shirai, N., Kodaira, C., Nishino, M., Ikuma, M., Ishizaki, T. and Hishida, A. (2007) Evidence That the Degree and Duration of Acid Suppression Are Related to Helicobacter pylori Eradication by Triple Therapy. Helicobacter, 12, 317-323. https://doi.org/10.1111/j.1523-5378.2007.00508.x
|
[36]
|
Sachs, G., Scott, D.R. and Wen, Y. (2011) Gastric Infection by Helicobacter pylori. Current Gastroenterology Reports, 13, 540-546.
https://doi.org/10.1007/s11894-011-0226-4
|
[37]
|
Nakajima, T. (2016) Vonoprazan Efficacy for First-Line Treatment of Helicobacter pylori Infection–Evaluation of Drug-Susceptibility Breakpoint. Japanese Journal of Helicobacter Research, 18, 53-60.
|
[38]
|
Yang, J.C., Lin, C.J., Wang, H.L., Chen, J.D., Kao, J.Y., Shun, C.T., Lu, C.W., Lin, B.R., Shieh, M.J., Chang, M.C., Chang, Y.T., Wei, S.C., Lin, L.C., Yeh, W.C., Kuo, J.S., Tung, C.C., Leong, Y.L., Wang, T.H. and Wong, J.M. (2015) High-Dose Dual Therapy Is Superior to Standard First-Line or Rescue Therapy for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology, 13, 895-905.
|
[39]
|
Attumi, T.A. and Graham, D.Y. (2014) High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy for Helicobacter pylori Infections. Helicobacter, 19, 319-322. https://doi.org/10.1111/hel.12126
|
[40]
|
Furuta, T., Sahara, S., Ichikawa, H., Kagami, T., Uotani, T., Yamade, M., Sugimoto, M., Hamaya, Y., Iwaizumi, M., Osawa, S. and Sugimoto, K. (2016) Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Standard PPI-Based Triple Therapy with Amoxicillin and Clarithromycin or Metronidazole in Japan. Gastroenterology, 150, S877.
|
[41]
|
Hsu, P.I., Lin, P.C. and Graham, D.Y. (2014) Hybrid Therapy for Helicobacter pylori Infection: A Systemic Review and Meta-Analysis. World Journal of Gastroenterology, 19, 319-322.
|
[42]
|
Sugimoto, M., Ban, H., Hira, D., Kamiya, T., Otsuka, T., Inatomi, O., Bamba, S., Terada, T. and Andoh, A. (2017) Letter: CYP3A4/5 Genotype Status and Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy in Japan. Alimentary Pharmacology & Therapeutics, 45, 1009-1010.
https://doi.org/10.1111/apt.13959
|
[43]
|
Hashinaga, M., Okimoto, T., Kodama, M., Mizukami, K., Ogawa, R., Okamoto, K., Shuto, M., Fukuda, K., Sonoda, H., Fukuda, M., Honda, S., Yamaoka, Y. and Murakami, K. (2016) わが国における薬剤耐性Helicobacter pyloriの現状—2013-2014年度耐性菌サーベイランスの集計報告. [Current Status of Drug Resistance Helicobacter Pylori in Japan—Total Report of Resistant Bacterial Surveillance for 2013 to 2014.] Japanese Journal of Helicobacter Research, 45-49. (In Japanese)
|
[44]
|
Furuta, T., Sugimoto, M., Yamade, M., Uotani, T., Sahara, S., Ichikawa, H., Yamada, T., Osawa, S., Sugimoto, K., Watanabe, H. and Umemura, K. (2014) Effect of Dosing Schemes of Amoxicillin on Eradication Rates of Helicobacter pylori with Amoxicillin-Based Triple Therapy. The Journal of Clinical Pharmacology, 54, 258-266. https://doi.org/10.1002/jcph.195
|